These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33575430)

  • 21. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.
    Kaštánková I; Štach M; Žižková H; Ptáčková P; Šmilauerová K; Mucha M; Šroller V; Otáhal P
    Mol Ther Methods Clin Dev; 2021 Dec; 23():119-127. PubMed ID: 34631931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.
    Marín Morales JM; Münch N; Peter K; Freund D; Oelschlägel U; Hölig K; Böhm T; Flach AC; Keßler J; Bonifacio E; Bornhäuser M; Fuchs A
    Front Immunol; 2019; 10():38. PubMed ID: 30778344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal CARs, universal T cells, and universal CAR T cells.
    Zhao J; Lin Q; Song Y; Liu D
    J Hematol Oncol; 2018 Nov; 11(1):132. PubMed ID: 30482221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.
    Machietto R; Giacobbe N; Perazzelli J; Hofmann TJ; Barz Leahy A; Grupp SA; Wang Y; Kadauke S
    J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
    Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
    Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.
    Vedvyas Y; McCloskey JE; Yang Y; Min IM; Fahey TJ; Zarnegar R; Hsu YS; Hsu JM; Van Besien K; Gaudet I; Law P; Kim NJ; Hofe EV; Jin MM
    Sci Rep; 2019 Jul; 9(1):10634. PubMed ID: 31337787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation.
    Tittlbach H; Schneider A; Strobel J; Zimmermann R; Maas S; Gebhardt B; Rauser G; Mach M; Mackensen A; Winkler TH; Winkler J
    J Transl Med; 2017 Nov; 15(1):228. PubMed ID: 29115976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.
    Wiesinger M; März J; Kummer M; Schuler G; Dörrie J; Schuler-Thurner B; Schaft N
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31426437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paving the way towards universal treatment with allogenic T cells.
    Townsend MH; Bennion K; Robison RA; O'Neill KL
    Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Manufacturing chimeric antigen receptor T cells: issues and challenges.
    Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
    Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
    Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
    Front Immunol; 2020; 11():99. PubMed ID: 32117253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
    Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
    Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.